Optimal time to provide skin cancer and photoprotection education to pediatric solid organ transplant recipients To the Editor: Skin cancer is the most frequent malignancy in pediatric patients after renal transplantation. 1 In children with other solid organ transplants, only posttransplant lymphoproliferative disease is more common.
1,2 A large percentage of a person's lifetime sun exposure occurs before 18 to 21 years of age; estimates range from 25% to 50%. 3 Required immunosuppressive treatment during this window contributes to an increased risk for skin cancer in pediatric organ transplant recipients (POTRs). Because POTRs may face complicated medical regimens and restrictions posttransplantation, they and their guardians may prefer to delay skin cancer education, as has been documented for adult renal transplant patients. 4 Our study assessed when POTRs and their guardians felt ready to (1) receive initial skin cancer and photoprotection education, (2) start using photoprotection measures, and (3) receive followup education. After approval by the Washington University School of Medicine Institutional Review Board, we surveyed 50 families with POTRs \18 years of age during routine posttransplant clinic visits with their transplant teams. Twenty-five families included children \7 years of age (guardian only participation) and 25 included children $7 years of age (child and guardian participation). All children $7 years of age signed assent and guardians signed consent for participation.
Participants completed questionnaires (child and adult versions) about medical history, skin type, skin cancer knowledge, and preferred timing of skin cancer and photoprotection education. Questions about their preference for timing of skin cancer education were repeated after an educational section with information about skin cancer in transplant recipients to determine whether basic knowledge about skin cancer risk affected the desired timing of skin cancer education.
Participant characteristics are shown in Table I . Eighty-five percent of guardians and 73% of children believed the best time to receive initial brief photoprotection and skin cancer education is before or immediately after transplantation. After receiving basic knowledge about their child's risk for skin cancer, guardians' preferences for this early education rose significantly (P ¼ .03) to 94% (Fig 1) . Eighty-eight percent of guardians and 68% of children also felt ready to start using photoprotection behaviors during this time frame, and 73% and 64%, respectively, believed that the best time to receive educational reminders is once per year or more often. The median age of children at the time of transplant was 3.7 years. Guardians with younger children (\3.7 years of age) at the time of transplant tended to prefer later education (23% vs. 10%), though the difference was not significant (P ¼ .24), possibly because of the small sample size.
We found a striking discrepancy in the responses between children and their guardians when asked if someone had talked to them about photoprotection and the risk for skin cancer posttransplant; children were much less aware (Table I) , showing a need for improved communication.
Our results show that POTRs and their guardians prefer to receive skin cancer and photoprotection education before or immediately after transplant, which is earlier than that found in adult renal transplant recipients. This knowledge should influence the dermatologic care and counseling of POTRs and their guardians as well as the development of pediatric-specific educational materials. Moving forward, our study can inform research on the adoption and habituation of sun-protective behaviors in POTRs, especially as they age and transition to adulthood.
We thank Washington University School of Medicine/ St. Louis Children's Hospital renal, liver, cardiac, and pulmonary transplant services. Oral JAK inhibitors have been associated with adverse effects including serious infections in up to 2%-6% of patients. 4 Topical formulations might offer decreased risk compared with systemic therapy. To date, there has been 1 report of a teenage girl with alopecia universalis who experienced significant hair regrowth with use of ruxolitinib 0.6% cream. 5 We report 6 pediatric AA patients treated with topical JAK inhibitors. Our findings are summarized in Table I . Topical preparations included tofacitinib and ruxolitinib creams in 1% and 2% formulations 
